Endoscopic Fecal Microbiota Transplantation "First-Line'' Treatment for Severe Clostridium difficile Infection?
*Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY †Centre for Digestive Diseases, Australia. Journal of clinical gastroenterology
(Impact Factor: 3.5).
06/2011; 45(8):655-7. DOI: 10.1097/MCG.0b013e3182257d4f
Available from: Stanislaw P. Stawicki
- "All 12 patients (100%) experienced complete clinical response, supporting the clinical safety and efficacy of colonoscopyadministered FMT. Brandt et al. (2011)  An editorial highlighting FMT as a proposed first-line therapy for severe C. difficile infection The authors provide a brief overview of the literature describing the magnitude of the C. difficile problem in the modern healthcare environment. "
[Show abstract] [Hide abstract]
ABSTRACT: Fecal microbiota transplantation (FMT) has emerged as a viable adjunct to traditional therapies used in the treatment of Clostridium difficile colitis. Despite the encouraging early results, wider implementation of FMT continues to be limited by the paucity of high-quality clinical evidence and logistical challenges. The purpose of this evidence table is to present the reader with the most up-to-date information (years 2010-2015) regarding clinical FMT applications, including novel methods of delivery and outcome-based focus.
Available from: Kieran C O'Doherty
- "Several systematic review papers have claimed high effectiveness rates for recurrent CDI and other gastrointestinal disorders (e.g., van Nood, Speelman, Kujiper, and Keller, 2009, reported 91% [159 patients] and Landy et al., 2011, reported 87% [145/166 patients] for CDI). Brandt, Borody, and Campbell (2011) have suggested that fecal transplants be considered as a first-line treatment for recurrent CDI, citing the high effectiveness rate and cost-effectiveness in comparison with antibiotics. The documentation of effectiveness, however, has often relied on retrospective review of case reports (Guo et al., 2011). "
[Show abstract] [Hide abstract]
ABSTRACT: Advances in human microbiome research have generated considerable interest in elucidating the role of bacteria in health and the application of microbial ecosystem therapies and probiotics. Fecal transplants involve the introduction of gut microbes from a healthy donor's stool to the patient and have been documented as effective for treating Clostridium difficile infections (CDIs) and some other gastrointestinal disorders. However, the treatment has encountered regulatory hurdles preventing widespread uptake. We examined dominant representations of fecal transplants in Canadian media and found that fecal transplants are often represented as being inherently disgusting or distasteful (the "ick factor"). This "ick factor" is used to construct different messages about the treatment's social acceptability and legitimacy. We conclude that an over-emphasis on the "ick factor" constrains public discourse from a more nuanced discussion of the social challenges, scientific concerns, and regulatory issues surrounding the treatment.
© The Author(s) 2015.
Available from: journalagent.com
- "Yalnız vankomisin alan hasta grubunda iyileşme %31, vankomisin alan ve bağırsak lavajı yapılan hastalarda %23 olarak bulunmuştur. İMT'nin, ilk kez geçirilen CDE'de dahi, kolon florasının dengesinin yeniden kurulması, hızlı etkisi, risklerin düşük olması, görece düşük maliyeti nedeniyle ilk tedavi seçeneği olabileceği tartışılmaktadır. Vakaların çok azında geçici karın ağrısı, ishal ya da birkaç hafta süren kabızlık bildirilmiştir.. "
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.